New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
07:33 EDTEPZMEpizyme reports Q2 EPS (40c), consensus (50c)
Reports Q2 revenue $9.49M, consensus $7.58M. Expects to end 2014 with more than $170M in cash and cash equivalents, it believes will fund the company until at least mid-2016, prior to including any potential future milestone payments.
News For EPZM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
08:06 EDTEPZMEpizyme announces resignation of Chief Medical Officer Eric Hedrick
Epizyme announced that Chief Medical Officer Eric Hedrick, M.D., has resigned from the company, effective October 31, 2014. Dr. Hedrick has agreed to assist Epizyme in an advisory capacity through the end of 2014. Peter Ho, M.D., Ph.D., who joined the company in September as Chief Development Officer, will continue to oversee the company’s clinical development, regulatory and translational medicine functions.
October 23, 2014
08:30 EDTEPZMEpizyme announces notice of allowance for U.S. patent applications
Epizyme announced that the US Patent and Trademark Office has granted Notices of Allowance for US Patent Applications, Nos. 14/136,551 and 14/136,738, both entitled “PRMT5 Inhibitors and Uses Thereof.” The allowed claims cover inhibitors of PRMT5 and methods of cancer treatment with PRMT5 inhibitors. PRMT5 is implicated in several cancers, including blood cancers. Epizyme also announced the publication of 10 patent applications covering chemical matter targeting several additional HMTs: CARM1, PRMT1, PRMT3, PRMT6 and PRMT8. These additional HMT targets are implicated in a variety of solid tumors and hematologic malignancies.
October 17, 2014
08:05 EDTEPZMEpizyme presents EPZ-6438 pre-clinical data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use